Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is a...
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
About this item
Full title
Author / Creator
Publisher
Athens: D.A. Spandidos
Journal title
Language
English
Formats
Publication information
Publisher
Athens: D.A. Spandidos
Subjects
More information
Scope and Contents
Contents
Drug-resistance is a major contributing factor for the poor prognosis in patients with pancreatic cancer. We have shown previously that the irreversible ErbB family blocker afatinib, is more effective than the reversible EGFR tyrosine kinase inhibitor erlotinib in inhibiting the growth of human pancreatic cancer cells. The aim of this study was to...
Alternative Titles
Full title
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4750538
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4750538
Other Identifiers
ISSN
1019-6439
E-ISSN
1791-2423
DOI
10.3892/ijo.2016.3320
